Teriparatide and denosumab, alone or combined, in women with postmenopausal osteoporosis: the DATA study randomised trial

Reid, 2006, Alendronic acid produces greater effects than risedronic acid on bone density and turnover in postmenopausal women with osteoporosis: results of FACTS- international, Clin Drug Invest, 26, 63, 10.2165/00044011-200626020-00002

Liberman, 1995, Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis. The Alendronate Phase III Osteoporosis Treatment Study Group, N Engl J Med, 333, 1437, 10.1056/NEJM199511303332201

Adami, 2004, Efficacy and safety of ibandronate given by intravenous injection once every 3 months, Bone, 34, 881, 10.1016/j.bone.2004.01.007

Reid, 2002, Intravenous zoledronic acid in postmenopausal women with low bone mineral density, N Engl J Med, 346, 653, 10.1056/NEJMoa011807

Neer, 2001, Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis, N Engl J Med, 344, 1434, 10.1056/NEJM200105103441904

Cummings, 2009, Denosumab for prevention of fractures in postmenopausal women with osteoporosis, N Engl J Med, 361, 756, 10.1056/NEJMoa0809493

Lacey, 1998, Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation, Cell, 93, 165, 10.1016/S0092-8674(00)81569-X

Fisher, 2000, In vivo effects of bisphosphonates on the osteoclast mevalonate pathway, Endocrinology, 141, 4793, 10.1210/endo.141.12.7921

Finkelstein, 2003, The effects of parathyroid hormone, alendronate, or both in men with osteoporosis, N Engl J Med, 349, 1216, 10.1056/NEJMoa035725

Black, 2003, The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis, N Engl J Med, 349, 1207, 10.1056/NEJMoa031975

Finkelstein, 2010, Effects of teriparatide, alendronate, or both in women with postmenopausal osteoporosis, J Clin Endocrinol Metab, 95, 1838, 10.1210/jc.2009-1703

Cosman, 2011, Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1–34)] in postmenopausal osteoporosis, J Bone Miner Res, 26, 503, 10.1002/jbmr.238

Kostenuik, 2001, OPG and PTH-(1–34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats, Endocrinology, 142, 4295, 10.1210/endo.142.10.8437

Pierroz, 2010, Are osteoclasts needed for the bone anabolic response to parathyroid hormone? A study of intermittent parathyroid hormone with denosumab or alendronate in knock-in mice expressing humanized RANKL, J Biol Chem, 285, 28164, 10.1074/jbc.M110.101964

Samadfam, 2007, Co-treatment of PTH with osteoprotegerin or alendronate increases its anabolic effect on the skeleton of oophorectomized mice, J Bone Miner Res, 22, 55, 10.1359/jbmr.060915

Black, 2001, An assessment tool for predicting fracture risk in postmenopausal women, Osteoporos Int, 12, 519, 10.1007/s001980170072

Muschitz, 2013, Antiresorptives overlapping ongoing teriparatide treatment result in additional increases in bone mineral density, J Bone Miner Res, 28, 196, 10.1002/jbmr.1716

Finkelstein, 2006, Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men, J Clin Endocrinol Metab, 91, 2882, 10.1210/jc.2006-0190

Delmas, 1995, The anabolic effect of human PTH (1–34) on bone formation is blunted when bone resorption is inhibited by the bisphosphonate tiludronate—is activated resorption a prerequisite for the in vivo effect of PTH on formation in a remodeling system?, Bone, 16, 603, 10.1016/8756-3282(95)00113-R

Ma, 2006, Teriparatide increases bone formation in modeling and remodeling osteons and enhances IGF-II immunoreactivity in postmenopausal women with osteoporosis, J Bone Miner Res, 21, 855, 10.1359/jbmr.060314

Chen, 2006, Change in lumbar spine BMD and vertebral fracture risk reduction in teriparatide-treated postmenopausal women with osteoporosis, J Bone Miner Res, 21, 1785, 10.1359/jbmr.060802

Austin, 2012, FREEDOM Trial. Relationship between bone mineral density changes with denosumab treatment and risk reduction for vertebral and nonvertebral fractures, J Bone Miner Res, 27, 687, 10.1002/jbmr.1472